Proliferative Diabetic Retinopathy (PDR) Global Market Report 2024

Description

“Proliferative Diabetic Retinopathy (PDR) Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on proliferative diabetic retinopathy (pdr) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
Measure the impact of high global inflation on market growth.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for proliferative diabetic retinopathy (pdr)? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The proliferative diabetic retinopathy (pdr) market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

1) By Treatment Type: Anti-VEGF (Vascular Endothelial Growth Factor) Therapy; Intraocular Steroids; Laser Surgery; Vitrectomy
2) By Mode of Administration: Injectables; Oral; Other Mode Of Administrations
3) By Application: Hospitals; Clinics; Other Applications
Companies Mentioned: Pfizer Inc.; Johnson and Johnson Limited; F. Hoffmann-La Roche Ltd.; Merck and Co. Inc.; AbbVie Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Proliferative diabetic retinopathy (PDR) represents an advanced stage of diabetic eye disease marked by the development of abnormal blood vessels in the retina. This occurrence is primarily attributed to prolonged high levels of blood sugar. If left unaddressed, these abnormal vessels can result in retinal bleeding, scarring, and impaired vision. Consequently, regular eye examinations are of paramount importance for early detection and effective management.

The primary treatment options for proliferative diabetic retinopathy encompass anti-VEGF (vascular endothelial growth factor) therapy, intraocular steroids, laser surgery, and vitrectomy. Intraocular steroids involve the direct administration of medications into the eye, which serves to address inflammation and manage conditions like diabetic macular edema or uveitis. This approach aids in reducing swelling and enhancing visual outcomes. Various modes of administration, including injectables, oral medications, and others, find application in settings such as hospitals, clinics, and more.

The proliferative diabetic retinopathy market research report is one of a series of new reports from The Business Research Company that provides proliferative diabetic retinopathy market statistics, including proliferative diabetic retinopathy industry global market size, regional shares, competitors with a proliferative diabetic retinopathy market share, detailed proliferative diabetic retinopathy market segments, market trends and opportunities and any further data you may need to thrive in the proliferative diabetic retinopathy industry. This proliferative diabetic retinopathy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The proliferative diabetic retinopathy (pdr) market size has grown rapidly in recent years. It will grow from $2.16 billion in 2023 to $2.42 billion in 2024 at a compound annual growth rate (CAGR) of 11.7%. The growth in the historic period can be attributed to growing diabetes prevalence, changes in lifestyle and intake of unhealthy foods, government initiatives, rising numbers of diabetes-related loss of vision.

The proliferative diabetic retinopathy (pdr) market size is expected to see rapid growth in the next few years. It will grow to $3.62 billion in 2028 at a compound annual growth rate (CAGR) of 10.6%. The growth in the forecast period can be attributed to aging population, public awareness and education about diabetes, research and development funding, rising demand for combination therapies. Major trends in the forecast period include advancements in diagnostic technologies, innovations in treatment options, artificial intelligence (ai) for early diagnosis, gene therapy advancements, advanced retinal imaging.

The increasing prevalence of diabetes is anticipated to be a significant driver for the future growth of the proliferative diabetic retinopathy (PDR) market. Diabetes, a chronic medical condition characterized by elevated blood glucose levels, stands as the primary contributor to proliferative diabetic retinopathy. Various treatments are available to prevent further damage to the retina and preserve vision in individuals with diabetes. For instance, as reported by the International Diabetes Federation (IDF), a Belgium-based organization, the year 2021 witnessed 537 million adults between the ages of 20-79 affected by diabetes, which translates to 1 in 10 people. This number is projected to increase to around 643 million by 2030 and further to 783 million by 2045. As a result, the rising prevalence of diabetes serves as a driving force behind the growth of the proliferative diabetic retinopathy (PDR) market.

The increasing prevalence of obesity is expected to be a key driver for the future growth of the proliferative diabetic retinopathy (PDR) market. Obesity, a multifaceted, chronic condition with various contributing factors, results in an excess accumulation of body fat and potential health issues. Obesity is closely associated with insulin resistance, chronic low-grade inflammation, and heightened oxidative stress, all of which can adversely affect the retinal microvasculature and contribute to the onset of diabetic retinopathy. For instance, according to a 2022 report released by Trust for America's Health, a non-profit organization in the United States, obesity rates in the country are on the rise, with four out of every ten American adults being affected by obesity. This represents an increase compared to the previous year, with 19 states reporting adult obesity rates exceeding 35%, up from 16 states in the preceding year. Consequently, the escalating prevalence of obesity serves as a pivotal catalyst driving the expansion of the proliferative diabetic retinopathy (PDR) market.

High treatment costs serve as a deterrent to the growth of the proliferative diabetic retinopathy (PDR) market during the projected period. The expenses associated with diagnosing and treating PDR can pose a significant financial burden, often reaching prohibitive levels. This encompasses the costs related to frequent eye examinations, laser therapy, and, in certain cases, surgical interventions. These elevated treatment expenses create financial challenges for both patients and healthcare systems. For instance, in 2023, as reported by Medical News Today, individuals typically face annual management costs ranging from $600 to $1,000 for the treatment of diabetic eye disease, while the cost of a vitrectomy procedure falls within the range of $8,000 to $14,000. As a result, the high treatment costs emerge as a constraining factor, impeding the growth of the proliferative diabetic retinopathy (PDR) market.

Prominent companies operating in the proliferative diabetic retinopathy market maintain a consistent focus on the development of groundbreaking therapies. This strategic emphasis aims to enhance treatment efficacy, alleviate the treatment-related financial burden, and ultimately elevate patient outcomes. For instance, in June 2022, Biogen, a leading US-based biotechnology company, partnered with Samsung Bioepis, a South Korea-based biotech company, to introduce Byooviz (ranibizumab-nuna). Byooviz represents the first ophthalmology biosimilar in the United States, offering treatment options for patients dealing with diabetic macular edema, proliferative diabetic retinopathy, neovascular age-related macular degeneration (wet AMD), and choroidal neovascularization. These innovative therapies are poised to bring transformative changes to the landscape of proliferative diabetic retinopathy treatment.

In September 2021, AbbVie, a pharmaceutical company based in the United States, and REGENXBIO Inc. entered into a collaborative partnership, the financial details of which have not been disclosed. This strategic alliance is driven by a shared objective includes the development and commercialization of RGX-314, a potential one-time gene therapy specifically crafted to address conditions like wet age-related macular degeneration (wet AMD), diabetic retinopathy (DR), and other chronic retinal diseases. At present, RGX-314 is undergoing a pivotal trial focused on wet AMD, employing a subretinal administration approach. Simultaneously, separate Phase II clinical trials are underway for both wet AMD and DR, with the utilization of in-office suprachoroidal delivery. Notably, REGENXBIO Inc., a US-based company renowned for its work in developing treatments for proliferative diabetic retinopathy (PDR), plays an integral role in this collaborative effort.

Major players in the proliferative diabetic retinopathy (pdr) market are Pfizer Inc., Johnson and Johnson Limited, F. Hoffmann-La Roche Ltd., Merck and Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GSK PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Novo Nordisk A/S, Boehringer Ingelheim International GmbH, Merck KGaA, Kubota Vision Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Mylan N.V., Santen Pharmaceutical Co. Ltd., Lupin Limited, Genentech Inc., Sirnaomics Inc.

North America was the largest region in the proliferative diabetic retinopathy market in 2023. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in proliferative diabetic retinopathy (PDR) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the proliferative diabetic retinopathy (PDR) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The proliferative diabetic retinopathy (PDR) market consists of sales of laser therapy, systemic therapies and combination therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. The proliferative diabetic retinopathy (PDR) market also includes sales of corticosteroids, ranibizumab, bevacizumab and fluocinolone acetonide drugs. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Product Code: r12257

1. Executive Summary

2. Proliferative Diabetic Retinopathy (PDR) Market Characteristics

3. Proliferative Diabetic Retinopathy (PDR) Market Trends And Strategies

4. Proliferative Diabetic Retinopathy (PDR) Market - Macro Economic Scenario

4.1. Impact Of High Inflation On The Market
4.2. Ukraine-Russia War Impact On The Market
4.3. COVID-19 Impact On The Market

5. Global Proliferative Diabetic Retinopathy (PDR) Market Size and Growth

5.1. Global Proliferative Diabetic Retinopathy (PDR) Market Drivers and Restraints
- 5.1.1. Drivers Of The Market
- 5.1.2. Restraints Of The Market
5.2. Global Proliferative Diabetic Retinopathy (PDR) Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
5.3. Global Proliferative Diabetic Retinopathy (PDR) Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Proliferative Diabetic Retinopathy (PDR) Market Segmentation

6.1. Global Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Anti-VEGF (Vascular Endothelial Growth Factor) Therapy
Intraocular Steroids
Laser Surgery
Vitrectomy
6.2. Global Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Mode of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Injectables
Oral
Other Mode Of Administrations
6.3. Global Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Hospitals
Clinics
Other Applications

7. Proliferative Diabetic Retinopathy (PDR) Market Regional And Country Analysis

7.1. Global Proliferative Diabetic Retinopathy (PDR) Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
7.2. Global Proliferative Diabetic Retinopathy (PDR) Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Proliferative Diabetic Retinopathy (PDR) Market

8.1. Asia-Pacific Proliferative Diabetic Retinopathy (PDR) Market Overview
Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.3. Asia-Pacific Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Mode of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.4. Asia-Pacific Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Proliferative Diabetic Retinopathy (PDR) Market

9.1. China Proliferative Diabetic Retinopathy (PDR) Market Overview
9.2. China Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.3. China Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Mode of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.4. China Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Proliferative Diabetic Retinopathy (PDR) Market

10.1. India Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.2. India Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Mode of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.3. India Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Proliferative Diabetic Retinopathy (PDR) Market

11.1. Japan Proliferative Diabetic Retinopathy (PDR) Market Overview
11.2. Japan Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.3. Japan Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Mode of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.4. Japan Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Proliferative Diabetic Retinopathy (PDR) Market

12.1. Australia Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.2. Australia Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Mode of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.3. Australia Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Proliferative Diabetic Retinopathy (PDR) Market

13.1. Indonesia Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.2. Indonesia Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Mode of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.3. Indonesia Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Proliferative Diabetic Retinopathy (PDR) Market

14.1. South Korea Proliferative Diabetic Retinopathy (PDR) Market Overview
14.2. South Korea Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.3. South Korea Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Mode of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.4. South Korea Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Proliferative Diabetic Retinopathy (PDR) Market

15.1. Western Europe Proliferative Diabetic Retinopathy (PDR) Market Overview
15.2. Western Europe Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.3. Western Europe Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Mode of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.4. Western Europe Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Proliferative Diabetic Retinopathy (PDR) Market

16.1. UK Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.2. UK Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Mode of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.3. UK Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Proliferative Diabetic Retinopathy (PDR) Market

17.1. Germany Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.2. Germany Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Mode of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.3. Germany Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Proliferative Diabetic Retinopathy (PDR) Market

18.1. France Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.2. France Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Mode of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.3. France Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Proliferative Diabetic Retinopathy (PDR) Market

19.1. Italy Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.2. Italy Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Mode of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.3. Italy Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Proliferative Diabetic Retinopathy (PDR) Market

20.1. Spain Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.2. Spain Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Mode of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.3. Spain Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Proliferative Diabetic Retinopathy (PDR) Market

21.1. Eastern Europe Proliferative Diabetic Retinopathy (PDR) Market Overview
21.2. Eastern Europe Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.3. Eastern Europe Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Mode of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.4. Eastern Europe Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Proliferative Diabetic Retinopathy (PDR) Market

22.1. Russia Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.2. Russia Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Mode of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.3. Russia Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Proliferative Diabetic Retinopathy (PDR) Market

23.1. North America Proliferative Diabetic Retinopathy (PDR) Market Overview
23.2. North America Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.3. North America Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Mode of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.4. North America Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Proliferative Diabetic Retinopathy (PDR) Market

24.1. USA Proliferative Diabetic Retinopathy (PDR) Market Overview
24.2. USA Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.3. USA Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Mode of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.4. USA Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Proliferative Diabetic Retinopathy (PDR) Market

25.1. Canada Proliferative Diabetic Retinopathy (PDR) Market Overview
25.2. Canada Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.3. Canada Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Mode of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.4. Canada Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Proliferative Diabetic Retinopathy (PDR) Market

26.1. South America Proliferative Diabetic Retinopathy (PDR) Market Overview
26.2. South America Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.3. South America Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Mode of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.4. South America Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Proliferative Diabetic Retinopathy (PDR) Market

27.1. Brazil Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.2. Brazil Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Mode of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.3. Brazil Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Proliferative Diabetic Retinopathy (PDR) Market

28.1. Middle East Proliferative Diabetic Retinopathy (PDR) Market Overview
28.2. Middle East Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.3. Middle East Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Mode of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.4. Middle East Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Proliferative Diabetic Retinopathy (PDR) Market

29.1. Africa Proliferative Diabetic Retinopathy (PDR) Market Overview
29.2. Africa Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.3. Africa Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Mode of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.4. Africa Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Proliferative Diabetic Retinopathy (PDR) Market Competitive Landscape And Company Profiles

30.1. Proliferative Diabetic Retinopathy (PDR) Market Competitive Landscape
30.2. Proliferative Diabetic Retinopathy (PDR) Market Company Profiles
- 30.2.1. Pfizer Inc.
  - 30.2.1.1. Overview
  - 30.2.1.2. Products and Services
  - 30.2.1.3. Strategy
  - 30.2.1.4. Financial Performance
- 30.2.2. Johnson and Johnson Limited
  - 30.2.2.1. Overview
  - 30.2.2.2. Products and Services
  - 30.2.2.3. Strategy
  - 30.2.2.4. Financial Performance
- 30.2.3. F. Hoffmann-La Roche Ltd.
  - 30.2.3.1. Overview
  - 30.2.3.2. Products and Services
  - 30.2.3.3. Strategy
  - 30.2.3.4. Financial Performance
- 30.2.4. Merck and Co. Inc.
  - 30.2.4.1. Overview
  - 30.2.4.2. Products and Services
  - 30.2.4.3. Strategy
  - 30.2.4.4. Financial Performance
- 30.2.5. AbbVie Inc.
  - 30.2.5.1. Overview
  - 30.2.5.2. Products and Services
  - 30.2.5.3. Strategy
  - 30.2.5.4. Financial Performance

31. Proliferative Diabetic Retinopathy (PDR) Market Other Major And Innovative Companies

31.1. Bayer AG
31.2. Novartis AG
31.3. Sanofi S.A.
31.4. Bristol-Myers Squibb Company
31.5. AstraZeneca plc
31.6. GSK plc
31.7. Takeda Pharmaceutical Company Limited
31.8. Eli Lilly and Company
31.9. Amgen Inc.
31.10. Novo Nordisk A/S
31.11. Boehringer Ingelheim International GmbH
31.12. Merck KGaA
31.13. Kubota Vision Inc.
31.14. Teva Pharmaceutical Industries Ltd.
31.15. Regeneron Pharmaceuticals Inc.

32. Global Proliferative Diabetic Retinopathy (PDR) Market Competitive Benchmarking

33. Global Proliferative Diabetic Retinopathy (PDR) Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Proliferative Diabetic Retinopathy (PDR) Market

35. Proliferative Diabetic Retinopathy (PDR) Market Future Outlook and Potential Analysis

35.1 Proliferative Diabetic Retinopathy (PDR) Market In 2028 - Countries Offering Most New Opportunities
35.2 Proliferative Diabetic Retinopathy (PDR) Market In 2028 - Segments Offering Most New Opportunities
35.3 Proliferative Diabetic Retinopathy (PDR) Market In 2028 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer